+------------------------------------------------------------------------------+
Actelion Rises After Citi Says It Could Be M&A Target for Astra 2013-11-21 09:37:51.247 GMT
By Simeon Bennett Nov. 21 (Bloomberg) -- Actelion climbs 4.6% to intraday record of CHF77.65; vol 72% of 3-mo avg. * Actelion is “an intriguing potential target” for AstraZeneca, Citigroup analyst Andrew Baum says in a note today * Buying Actelion could provide 12% EBIT accretion for Astra, Baum says Note: Actelion’s Next $1 Billion Drug Seen Enticing Buyers: Real M&A
For Related News and Information: First Word scrolling panel: FIRST <GO> First Word newswire: NH BFW<GO>
To contact the reporter on this story: Simeon Bennett in Geneva at +41-22-317-9238 or sbennett9@bloomberg.net
To contact the editor responsible for this story: Phil Serafino at +33-1-5530-6277 or pserafino@bloomberg.net